Integration of an automated insulin delivery system with a one-year continuous glucose monitoring system by Sequel Med Tech and Senseonics announced
In an exciting development for people living with diabetes, Sequel Med Tech and Senseonics Holdings have entered a commercial agreement to integrate Sequel's twiist Automated Insulin Delivery (AID) System with Senseonics' Eversense 365 continuous glucose monitoring (CGM) system [1][2][5]. This integrated product is set for a commercial launch in Q4 2025.
The integration of twiist with Eversense 365 aims to create a seamless diabetes management solution. Eversense 365, the world's first and only one-year CGM system, will provide continuous glucose data, potentially improving insulin delivery decisions and glycemic control. Meanwhile, the twiist system, which uses sound wave technology for insulin delivery, offers advanced features such as personalized blood sugar targets as low as 87 mg/dL, intelligent meal absorption profiles, and predictive blood sugar forecasting updated every five minutes [3].
This collaboration represents a significant advance in automated insulin delivery technology. By integrating a long-term implantable CGM with a sophisticated AID pump offering customizable and predictive insulin dosing, the companies hope to target improved outcomes and patient convenience in type 1 diabetes management [1][3][5].
Senseonics funds this development partially through a recent capital raise and expects this combined system to further increase market presence and patient adoption [2]. The integration aligns with Senseonics' strategy to expand revenue streams in diabetes technology by leveraging its durable Eversense 365 CGM and partnering with innovators in insulin delivery.
Sequel Med Tech's CEO, Alan Lotvin, M.D., stated that the partnership with Senseonics is an investment in innovations that empower people with diabetes. People living with type 1 diabetes who choose to use twiist will have the flexibility to select from two compatible CGM partners, the Senseonics Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensor.
The companies are united by a shared commitment to simplifying diabetes management and improving quality of life. This collaboration aims to provide more tools for managing diabetes, potentially leading to improved glucose control, increased convenience, and greater flexibility.
In related news, Medtronic's MiniMed 780G system for diabetes has received CE Mark, and the Simplera Sync sensor for MiniMed 780G has received FDA approval. Meanwhile, another collaboration, between PharmaSens and SiBionics, is aimed at advancing the development of an all-in-one patch pump.
This partnership between Sequel Med Tech and Senseonics marks a significant step forward in transforming diabetes care. Senseonics' President and CEO, Tim Goodnow, PhD, said, "This collaboration is a significant step forward in transforming diabetes care by combining our long-term, implantable CGM system with Sequel's advanced insulin delivery system."
References: 1. Sequel Med Tech and Senseonics Collaborate to Integrate twiist AID System with Eversense 365 CGM 2. Sequel Med Tech and Senseonics Collaborate to Integrate twiist AID System with Eversense 365 CGM 3. Sequel Med Tech's twiist AID System: A New Era in Insulin Delivery 4. FDA Clears Eversense 365 as an Integrated Continuous Glucose Monitoring (iCGM) System for People with Diabetes 5. Sequel Med Tech and Senseonics Collaborate to Integrate twiist AID System with Eversense 365 CGM
- This collaboration between Sequel Med Tech and Senseonics could revolutionize the management of chronic diseases, particularly type-2 diabetes, by integrating science and technology to create a seamless health-and-wellness solution.
- The innovative integration of Sequel's twiist Automated Insulin Delivery (AID) System with Senseonics' Eversense 365 continuous glucose monitoring (CGM) system aims to offer a more accurate and personalized approach to medical-conditions management, like diabetes.
- As technological advancements continue to shape the landscape of health-and-wellness, the integrated twiist-Eversense 365 system presents a significant leap forward in addressing the unique needs of individuals living with chronic diseases, including type-1 diabetes, ultimately improving their quality of life.
